연구동향 분석
박사

구강암에서 Sorafenib, Parthenolide 그리고 Cryptotanshinone의 항암기전 연구 = Anti-cancer effects of Sorafenib, Parthenolide and Cryptotanshinone in human oral cancer

유현주 2016년

논문상세정보
인용/피인용
' 구강암에서 Sorafenib, Parthenolide 그리고 Cryptotanshinone의 항암기전 연구 = Anti-cancer effects of Sorafenib, Parthenolide and Cryptotanshinone in human oral cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Cryptotanshinone
  • Sorafenib
  • apopto-sis
  • oral cancer
  • parthenolide
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
782 0

0.0%

' 구강암에서 Sorafenib, Parthenolide 그리고 Cryptotanshinone의 항암기전 연구 = Anti-cancer effects of Sorafenib, Parthenolide and Cryptotanshinone in human oral cancer' 의 참고문헌

  • and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer research 61, 5137-5144.
  • Zhou, P., Qian, L., Kozopas, K. M., and Craig, R. W. (1997). Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89, 630-643.
  • Zhang, S., Ong, C. N., and Shen, H. M. (2004). Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer letters 208, 143-153.
  • Yu, X. Y., Lin, S. G., Chen, X., Zhou, Z. W., Liang, J., Duan, W., Chowbay, B., Wen, J. Y., Chan, E., Cao, J., et al. (2007b). Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Current drug metabolism 8, 365-378.
  • Yu, H., and Jove, R. (2004). The STATs of cancer--new molecular targets come of age. Nature reviews Cancer 4, 97-105.
  • Yu, H., Kortylewski, M., and Pardoll, D. (2007a). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature reviews Immunology 7, 41-51.
  • Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., and Adjei, A. A. (2005). The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869.
  • Yip-Schneider, M. T., Nakshatri, H., Sweeney, C. J., Marshall, M. S., Wiebke, E. A., and Schmidt, C. M. (2005). Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Molecular cancer therapeutics 4, 587-594.
  • Yang, F., Van Meter, T. E., Buettner, R., Hedvat, M., Liang, W., Kowolik, C. M., Mepani, N., Mirosevich, J., Nam, S., Chen, M. Y., et al. (2008).
  • Xiang, Y., Zhang, X., Nix, D. B., Katoh, T., Aoki, K., Tiemeyer, M., and Wang, Y. (2013). Regulation of protein glycosylation and sorting by the Golgi matrix proteins GRASP55/65. Nat Commun 4, 1659.
  • Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., and Kelley, S. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5, 835-844.
  • Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research 64, 7099-7109.
  • Wen, J., You, K. R., Lee, S. Y., Song, C. H., and Kim, D. G. (2002). Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. The Journal of biological chemistry 277, 38954-38964.
  • Turkson, J., and Jove, R. (2000). STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626.
  • Thornberry, N. A., and Lazebnik, Y. (1998). Caspases: enemies within. Science 281, 1312-1316.
  • Thompson, C. B., (1995), 'Apoptosis in the pathogenesis and treatment of disease;’,. Science, 267, 1456–1462.
  • Tang, R., Faussat, A. M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O., and Marie, J. P. (2006). Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Molecular cancer therapeutics 5, 723-731.
  • Sweeney, C. J., Mehrotra, S., Sadaria, M. R., Kumar, S., Shortle, N. H., Roman, Y., Sheridan, C., Campbell, R. A., Murry, D. J., Badve, S., and Nakshatri, H. (2005). The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular cancer therapeutics 4, 1004-1012.
  • Strumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H. J., and Schwartz, B. (2007). Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. The oncologist 12, 426-437.
  • Strasser, A. (2005). The role of BH3-only proteins in the immune system. Nature reviews Immunology 5, 189-200.
  • Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Molecular cancer therapeutics 7, 3519-3526.
  • Song, L., Coppola, D., Livingston, S., Cress, D., and Haura, E. B. (2005). Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer biology & therapy 4, 267-276.
  • Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007a). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America 104, 7391-7396.
  • Siddiquee, K. A., Gunning, P. T., Glenn, M., Katt, W. P., Zhang, S., Schrock, C., Sebti, S. M., Jove, R., Hamilton, A. D., and Turkson, J. (2007b). An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS chemical biology 2, 787- 798.
  • Shin, J. A., Kim, J. J., Choi, E. S., Shim, J. H., Ryu, M. H., Kwon, K. H., Park, H. M., Seo, J. Y., Lee, S. Y., Lim, D. W., et al. (2013b). In vitro apoptotic effects of methanol extracts of Dianthus chinensis and Acalypha australis L. targeting specificity protein 1 in human oral cancer cells. Head Neck 35, 992-998.
  • Shin, J. A., Jung, J. Y., Ryu, M. H., Safe, S., and Cho, S. D. (2013). Mithramycin A Inhibits Myeloid Cell Leukemia-1 to Induce Apoptosis in Oral Squamous Cell Carcinomas and Tumor Xenograft through Activation of Bax and Oligomerization. Molecular pharmacology 83, 33-41.
  • Shin, J. A., Han, G., Park, S. K., Lee, K., Kim, H. J., Cho, S. D., and Kim, H. (2013a). The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells. Oral Dis.
  • Shin, D. S., Kim, H. N., Shin, K. D., Yoon, Y. J., Kim, S. J., Han, D. C., and Kwon, B. M. (2009). Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer research 69, 193-202.
  • Schulze-Bergkamen, H., Fleischer, B., Schuchmann, M., Weber, A., Weinmann, A., Krammer, P. H., and Galle, P. R. (2006). Suppression of Mcl- 1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC cancer 6, 232.
  • Saadane, A., Masters, S., DiDonato, J., Li, J., and Berger, M. (2007). Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. American journal of respiratory cell and molecular biology 36, 728-736.
  • Rousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L., and Sonenberg, N. (1996). Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proceedings of the National Academy of Sciences of the United States of America 93, 1065-1070.
  • Rosato, R. R., Almenara, J. A., Dai, Y., and Grant, S. (2003). Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Molecular cancer therapeutics 2, 1273-1284.
  • Riedl, S. J., and Salvesen, G. S. (2007). The apoptosome: signalling platform of cell death. Nature reviews Molecular cell biology 8, 405-413.
  • Reynolds, J. E., Li, J., Craig, R. W., and Eastman, A. (1996). BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Experimental cell research 225, 430-436.
  • Reed JC. 1997. Double identity for proteins of the Bcl-2 family. Nature. 387: 773-776.
  • Rahmani, M., Davis, E. M., Bauer, C., Dent, P., and Grant, S. (2005). Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. The Journal of biological chemistry 280, 35217-35227.
  • Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M., and Strasser, A. (1999). The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Molecular cell 3, 287-296.
  • Putcha, G. V., Moulder, K. L., Golden, J. P., Bouillet, P., Adams, J. A., Strasser, A., and Johnson, E. M. (2001). Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 29, 615-628.
  • Putcha, G. ., Moulder, K. L., Golden, J. P., Bouillet, P., Adams, J. A., Strasser, A., and Johnson, E. M. (2001). Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 29, 615-628.
  • Pongrakhananon, V., Stueckle, T. A., Wang, H. Y., O'Doherty, G. A., Dinu, C. Z., Chanvorachote, P., and Rojanasakul, Y. (2014). Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradation. Biochem Pharmacol 88, 23-35.
  • Park, J. H., Liu, L., Kim, I. H., Kim, J. H., You, K. R., and Kim, D. G. (2005). Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer research 65, 2804-2814.
  • Park, I. J., Kim, M. J., Park, O. J., Choe, W., Kang, I., Kim, S. S., and Ha, J. (2012). Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells. Apoptosis : an international journal on programmed cell death 17, 248-257.
  • Panka, D. J., Wang, W., Atkins, M. B., and Mier, J. W. (2006). The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer research 66, 1611-1619.
  • Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S., Akashi, K., and Korsmeyer, S. J. (2005). Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101-1104.
  • O'Reilly, L. A., Cullen, L., Visvader, J., Lindeman, G. J., Print, C., Bath, M. L., Huang, D. C., and Strasser, A. (2000). The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. The American journal of pathology 157, 449-461.
  • Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., and Wang, X. (2003). Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes & development 17, 1475-1486.
  • Nielsen, M., Kaestel, C. G., Eriksen, K. W., Woetmann, A., Stokkedal, T., Kaltoft, K., Geisler, C., Ropke, C., and Odum, N. (1999). Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 13, 735-738.
  • Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365. Natoni, F., Diolordi, L., Santoni, C., and Gilardini Montani, M. S. (2005). Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochimica et biophysica acta 1745, 318-329.
  • Nagata, M., Wada, K., Nakajima, A., Nakajima, N., Kusayama, M., Masuda, T., Iida, S., Okura, M., Kogo, M., and Kamisaki, Y. (2009). Role of myeloid cell leukemia-1 in cell growth of squamous cell carcinoma. Journal of pharmacological sciences 110, 344-353.
  • Moulding, D. A., Giles, R. V., Spiller, D. G., White, M. R., Tidd, D. M., and Edwards, S. W. (2000). Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood 96, 1756-1763.
  • Mora, L. B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., Bowman, T., Falcone, R., Fairclough, R., Cantor, A., et al. (2002). Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer research 62, 6659-6666.
  • Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P. H., and Peter, M. E. (1997). FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). The EMBO journal 16, 2794-2804.
  • McHugh, C. H., Roberts, D. B., El-Naggar, A. K., Hanna, E. Y., Garden, A. S., Kies, M. S., Weber, R. S., and Kupferman, M. E. (2012). Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer 118, 3928-3936.
  • Martin, A. P., Park, M. A., Mitchell, C., Walker, T., Rahmani, M., Thorburn, A., Haussinger, D., Reinehr, R., Grant, S., and Dent, P. (2009). BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular pharmacology 76, 327-341.
  • Maddika, S., Ande, S. R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., Eshraghi, M., Manda, K. D., Wiechec, E., and Los, M. (2007). Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 10, 13-29.
  • Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., and Carter, C. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer research 66, 11851- 11858.
  • Liu, H., Ma, Y., Cole, S. M., Zander, C., Chen, K. H., Karras, J., and Pope, R. M. (2003). Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102, 344-352.
  • Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501.
  • Li, H., Zhang, Q., Chu, T., Shi, H. Y., Fu, H. M., Song, X. R., Meng, W. T., Mao, S. J., and Jia, Y. Q. (2012). Growth-inhibitory and apoptosis-inducing effects of tanshinones on hematological malignancy cells and their structureactivity relationship. Anticancer Drugs 23, 846-855.
  • Lee, S. O., Lou, W., Qureshi, K. M., Mehraein-Ghomi, F., Trump, D. L., and Gao, A. C. (2004). RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60, 303-309.
  • Kwok, B. H., Koh, B., Ndubuisi, M. I., Elofsson, M., and Crews, C. M. (2001). The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chemistry & biology 8, 759-766.
  • Kuroda, J., Kamitsuji, Y., Kimura, S., Ashihara, E., Kawata, E., Nakagawa, Y., Takeuichi, M., Murotani, Y., Yokota, A., Tanaka, R., et al. (2008). Antimyeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. International journal of hematology 87, 507-515.
  • Kok, S. H., Yeh, C. C., Chen, M. L., and Kuo, M. Y. (2009). Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. Oral oncology 45, 1067-1072.
  • Knight, D. W. (1995). Feverfew: chemistry and biological activity. Natural product reports 12, 271-276.
  • Kim, J. H., Liu, L., Lee, S. O., Kim, Y. T., You, K. R., and Kim, D. G. (2005). Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer research 65, 6312-6320.
  • Kaufmann, S. H., Karp, J. E., Letendre, L., Kottke, T. J., Safgren, S., Greer, J., Gojo, I., Atherton, P., Svingen, P. A., Loegering, D. A., et al. (2005). Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 6641-6649.
  • Jin, Z., and El-Deiry, W. S. (2005). Overview of cell death signaling pathways. Cancer biology & therapy 4, 139-163.
  • Huang, S., and Sinicrope, F. A. (2010). Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Molecular cancer therapeutics 9, 742-750.
  • Hu, W., and Kavanagh, J. J. (2003). Anticancer therapy targeting the apoptotic pathway. The lancet oncology 4, 721-729.
  • Hirano, T., Ishihara, K., and Hibi, M. (2000). Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2556.
  • Hehner, S. P., Hofmann, T. G., Droge, W., and Schmitz, M. L. (1999). The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. Journal of immunology 163, 5617- 5623.
  • Han, J., Goldstein, L. A., Gastman, B. R., and Rabinowich, H. (2006). Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. The Journal of biological chemistry 281, 10153- 10163.
  • Gu, F. M., Li, Q. L., Gao, Q., Jiang, J. H., Huang, X. Y., Pan, J. F., Fan, J., and Zhou, J. (2011). Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 17, 3922-3932.
  • Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (1999). BCL-2 family members and the mitochondria in apoptosis. Genes & development 13, 1899- 1911.
  • Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 11-19.
  • Gridelli, C., Maione, P., Del Gaizo, F., Colantuoni, G., Guerriero, C., Ferrara, C., Nicolella, D., Comunale, D., De Vita, A., and Rossi, A. (2007). Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. The oncologist 12, 191-200.
  • Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M. Y., Zeng, Q., Pitt, A. S., and Tweardy, D. J. (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. The Journal of clinical investigation 102, 1385-1392.
  • Gojo, I., Zhang, B., and Fenton, R. G. (2002). The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clinical cancer research : an official journal of the American Association for Cancer Research 8, 3527-3538.
  • Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M., and Cook, S. J. (2009). Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. The FEBS journal 276, 6050- 6062.
  • Ge, Y., Cheng, R., Zhou, Y., Shen, J., Peng, L., Xu, X., Dai, Q., Liu, P., Wang, H., Ma, X., et al. (2012). Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem 368, 17-25.
  • Gao, L. F., Xu, D. Q., Shao, Y. T., Zhao, D., and Zhao, X. J. (2005). [Knockdown of STAT3 expression using siRNA inhibits the growth of prostate cancer cell lines]. Zhonghua nan ke xue = National journal of andrology 11, 29-33, 37.
  • Fecteau, J. F., Bharati, I. S., O'Hayre, M., Handel, T. M., Kipps, T. J., and Messmer, D. (2012). Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med 18, 19-28.
  • Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356, 125-134.
  • Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of clinical investigation 107, 351-362.
  • Duffy, M. J., O'Donovan, N., Brennan, D. J., Gallagher, W. M., and Ryan, B. M. (2007). Survivin: a promising tumor biomarker. Cancer letters 249, 49-60.
  • Ding, Q., Huo, L., Yang, J. Y., Xia, W., Wei, Y., Liao, Y., Chang, C. J., Yang, Y., Lai, C. C., Lee, D. F., et al. (2008). Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer research 68, 6109-6117.
  • Diaz, N., Minton, S., Cox, C., Bowman, T., Gritsko, T., Garcia, R., Eweis, I., Wloch, M., Livingston, S., Seijo, E., et al. (2006). Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 20-28.
  • Desagher, S., Osen-Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, S., Maundrell, K., Antonsson, B., and Martinou, J. C. (1999). Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. The Journal of cell biology 144, 891-901.
  • Derouet, M., Thomas, L., Cross, A., Moots, R. J., and Edwards, S. W. (2004). Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. The Journal of biological chemistry 279, 26915-26921.
  • Darnell, J. E., Jr. (2002). Transcription factors as targets for cancer therapy. Nature reviews Cancer 2, 740-749.
  • Darnell, J. E., Jr. (1997). STATs and gene regulation. Science 277, 1630- 1635.
  • Dai, Y., Rahmani, M., and Grant, S. (2003). Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22, 7108-7122.
  • Craig, R. W. (2002). MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16, 444-454.
  • Clohessy, J. G., Zhuang, J., de Boer, J., Gil-Gomez, G., and Brady, H. J. (2006). Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. The Journal of biological chemistry 281, 5750-5759.
  • Choi, K. H., Shim, J. H., Huong, L. D., Cho, N. P., and Cho, S. D. (2011). Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma. Oral diseases 17, 469-475.
  • Choi, E.S., Jung, J.Y., Lee, J.S., Park, J.H., Cho, N.P., and Cho, S.D. (2013). Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Lett 328, 65-72.
  • Choi, E. S., Shim, J. H., Jung, J. Y., Kim, H. J., Choi, K. H., Shin, J. A., Nam, J. S., Cho, N. P., and Cho, S. D. (2011). Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer science 102, 742-748.
  • Chen, W., Luo, Y., Liu, L., Zhou, H., Xu, B., Han, X., Shen, T., Liu, Z., Lu, Y., and Huang, S. (2010). Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res (Phila) 3, 1015-1025. Cheng, T. O. (2007). Cardiovascular effects of Danshen. International journal of cardiology 121, 9-22.
  • Chen, K. F., Tai, W. T., Liu, T. H., Huang, H. P., Lin, Y. C., Shiau, C. W., Li, P. K., Chen, P. J., and Cheng, A. L. (2010). Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clinical cancer research : an official journal of the American Association for Cancer Research 16, 5189-5199.
  • Chandana, S. R., and Conley, B. A. (2008). Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert review of anticancer therapy 8, 645-652.
  • Chai, S. K., Nichols, G. L., and Rothman, P. (1997). Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159, 4720-4728.
  • Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., et al. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115.
  • Carter, C. A., Chen, C., Brink, C., Vincent, P., Maxuitenko, Y. Y., Gilbert, K. S., Waud, W. R., and Zhang, X. (2007). Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer chemotherapy and pharmacology 59, 183-195.
  • Bromberg, J., and Wang, T. C. (2009). Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15, 79-80.
  • Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. (1999). Stat3 as an oncogene. Cell 98, 295-303.
  • Armstrong, J. S. (2006). Mitochondria: a target for cancer therapy. British journal of pharmacology 147, 239-248.
  • Antonsson, B., and Martinou, J. C. (2000). The Bcl-2 protein family. Experimental cell research 256, 50-57.
  • Alas, S., and Bonavida, B. (2003). Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research 9, 316-326. Bromberg, J., and Darnell, J. E., Jr. (2000). The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473.
  • Al Zaid Siddiquee, K., and Turkson, J. (2008). STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18, 254-267. Alas, S., and Bonavida, B. (2001). Rituximab inactivates signal transducer
  • Ahmad, T., and Eisen, T. (2004). Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 6388S-6392S.
  • Adams, J. M., and Cory, S. (2001). Life-or-death decisions by the Bcl-2 protein family. Trends in biochemical sciences 26, 61-66.
  • Adams, J. M., and Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326.
  • Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J. Y., Lathia, C., Schwartz, B., et al. (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24, 4293-4300.